Illinois 2023-2024 Regular Session

Illinois Senate Bill SB1402 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	SB1402 EngrossedLRB103 25360 KTG 51705 b SB1402 Engrossed LRB103 25360 KTG 51705 b
2		-	SB1402 Engrossed LRB103 25360 KTG 51705 b
	1	+	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1402 Introduced 2/6/2023, by Sen. Laura Fine SYNOPSIS AS INTRODUCED: 305 ILCS 65/15 new Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024. LRB103 25360 KTG 51705 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1402 Introduced 2/6/2023, by Sen. Laura Fine SYNOPSIS AS INTRODUCED: 305 ILCS 65/15 new 305 ILCS 65/15 new Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024. LRB103 25360 KTG 51705 b LRB103 25360 KTG 51705 b A BILL FOR
	2	+	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1402 Introduced 2/6/2023, by Sen. Laura Fine SYNOPSIS AS INTRODUCED:
	3	+	305 ILCS 65/15 new 305 ILCS 65/15 new
	4	+	305 ILCS 65/15 new
	5	+	Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024.
	6	+	LRB103 25360 KTG 51705 b LRB103 25360 KTG 51705 b
	7	+	LRB103 25360 KTG 51705 b
	8	+	A BILL FOR
	9	+	SB1402LRB103 25360 KTG 51705 b SB1402 LRB103 25360 KTG 51705 b
	10	+	SB1402 LRB103 25360 KTG 51705 b
3	11		1 AN ACT concerning public aid.
4	12		2 Be it enacted by the People of the State of Illinois,
5	13		3 represented in the General Assembly:
6	14		4 Section 5. The Early Mental Health and Addictions
7	15		5 Treatment Act is amended by adding Section 15 as follows:
8	16		6 (305 ILCS 65/15 new)
9	17		7 Sec. 15. Pilot program for 8-milligram naloxone nasal
10	18		8 spray kits.
11	19		9 (a) Findings. The General Assembly finds the following:
12	20		10 (1) In its May 2022 Statewide Semiannual Opioid
13	21		11 Report, the Department of Public Health reported that
14	22		12 3,013 fatalities occurred in 2021 due to opioid overdoses.
15	23		13 (2) These 3,013 opioid overdose deaths in Illinois
16	24		14 represent a 2.3% increase from 2020 and a 35.8% spike from
17	25		15 2019.
18	26		16 (3) In 2021, toxicology testing found that 2,672 or
19	27		17 89% of the opioid fatalities involved a synthetic opioid
20	28		18 such as fentanyl.
21	29		19 (4) A 4-milligram naloxone nasal spray has been the
22	30		20 principal tool for bystanders and emergency medical
23	31		21 service providers to revive an individual from an overdose
24	32		22 episode.
25	33		23 (5) A study published in the Harm Reduction Journal in
26	34
27	35
28	36
29		-	SB1402 Engrossed LRB103 25360 KTG 51705 b
	37	+	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB1402 Introduced 2/6/2023, by Sen. Laura Fine SYNOPSIS AS INTRODUCED:
	38	+	305 ILCS 65/15 new 305 ILCS 65/15 new
	39	+	305 ILCS 65/15 new
	40	+	Amends the Early Mental Health and Addictions Treatment Act. Requires the Department of Human Services to implement a 2-year pilot program to provide FDA-approved 8-milligram naloxone nasal spray kits to licensed community substance use providers and public health departments in Cook County, DuPage County, Winnebago County, Sangamon County, and St. Clair County. Requires the Department to implement a data collection program to determine the number of 8-milligram naloxone nasal spray kits administered by emergency medical service providers and bystanders per overdose incident during the 2-year term of the pilot program. Provides that the data collected must also include the number of overdose reversals and deaths following the administration of the 8-milligram naloxone nasal spray. Requires the Department to prepare a report on the results of the 2-year pilot program and submit the report to the General Assembly by July 1, 2026. Effective January 1, 2024.
	41	+	LRB103 25360 KTG 51705 b LRB103 25360 KTG 51705 b
	42	+	LRB103 25360 KTG 51705 b
	43	+	A BILL FOR
30	44
31	45
32		-	SB1402 Engrossed- 2 -LRB103 25360 KTG 51705 b SB1402 Engrossed - 2 - LRB103 25360 KTG 51705 b
33		-	SB1402 Engrossed - 2 - LRB103 25360 KTG 51705 b
	46	+
	47	+
	48	+
	49	+	305 ILCS 65/15 new
	50	+
	51	+
	52	+
	53	+	LRB103 25360 KTG 51705 b
	54	+
	55	+
	56	+
	57	+
	58	+
	59	+
	60	+
	61	+
	62	+
	63	+	SB1402 LRB103 25360 KTG 51705 b
	64	+
	65	+
	66	+	SB1402- 2 -LRB103 25360 KTG 51705 b SB1402 - 2 - LRB103 25360 KTG 51705 b
	67	+	SB1402 - 2 - LRB103 25360 KTG 51705 b
34	68		1 May 2022 surveyed 125 adult residents of the United States
35	69		2 who were administered a 4-milligram naloxone nasal spray
36	70		3 during an opioid overdose. The study found that 78% of the
37	71		4 adults surveyed reported using at least 2 or more doses of
38	72		5 the 4-milligram naloxone nasal spray. While 30% of the
39	73		6 adults surveyed reported using at least 3 or more doses of
40	74		7 the 4-milligram naloxone nasal spray.
41	75		8 (6) A 2021 article published in the Harm Reduction
42	76		9 Journal reported on a study conducted by the Johns Hopkins
43	77		10 Bloomberg School of Public Health which surveyed 171
44	78		11 people living in suburban Maryland who use opioids.
45	79		12 Sixty-one or 35.7% of the persons surveyed reported having
46	80		13 received take-home naloxone during the 6-month period
47	81		14 immediately prior to the start of the study. 57% of those
48	82		15 persons reported using it to reverse an overdose. Out of
49	83		16 that group of persons who had an overdose reversal, 79%
50	84		17 reported needing at least 2 or more doses of the take-home
51	85		18 naloxone.
52	86		19 (7) The National Library of Medicine recently
53	87		20 published a study that analyzed emergency medical services
54	88		21 (EMS) data collected and stored in the National Emergency
55	89		22 Medical Services Information System database. The study
56	90		23 examined data collected from over 10,000 EMS agencies
57	91		24 across 47 states concerning 946,000 EMS calls that
58	92		25 involved the administration of naloxone. The study found
59	93		26 that naloxone multi-dosing by emergency medical service
60	94
61	95
62	96
63	97
64	98
65		-	SB1402 ~~Engrossed~~ - 2 - LRB103 25360 KTG 51705 b
	99	+	SB1402 - 2 - LRB103 25360 KTG 51705 b
66	100
67	101
68		-	SB1402 ~~Engrossed~~- 3 -LRB103 25360 KTG 51705 b SB1402 ~~Engrossed~~ - 3 - LRB103 25360 KTG 51705 b
69		-	SB1402 ~~Engrossed~~ - 3 - LRB103 25360 KTG 51705 b
	102	+	SB1402- 3 -LRB103 25360 KTG 51705 b SB1402 - 3 - LRB103 25360 KTG 51705 b
	103	+	SB1402 - 3 - LRB103 25360 KTG 51705 b
70	104		1 providers increased 54% over 5 years, from 18.4% to 28.4%
71	105		2 in 2020.
72	106		3 (8) On April 30, 2021, the U.S. Food and Drug
73	107		4 Administration approved a higher 8-milligram dose naloxone
74	108		5 nasal spray product to treat opioid overdose.
75	109		6 (9) Thirty-three states have Naloxone Standing Orders
76	110		7 that authorize eligible entities to have open access to
77	111		8 the 8-milligram naloxone nasal spray. Those states are:
78	112		9 Ohio, Kentucky, Iowa, Pennsylvania, Massachusetts, New
79	113		10 Jersey, Virginia, Alabama, Florida, Tennessee, Colorado,
80	114		11 Alaska, New Hampshire, Illinois, Arizona, Kansas,
81	115		12 California, Texas, Georgia, South Carolina, North
82	116		13 Carolina, West Virginia, Michigan, Connecticut, Oklahoma,
83	117		14 Minnesota, Maine, Louisiana, Nevada, Idaho, Oregon,
84	118		15 Nebraska, and Vermont.
85	119		16 (10) Thirteen state government agencies have purchased
86	120		17 the 8-milligram naloxone nasal spray: Alabama, Alaska,
87	121		18 Colorado, Florida, Idaho, Iowa, Kentucky, New Hampshire,
88	122		19 Ohio, Pennsylvania, Tennessee, Wisconsin, and West
89	123		20 Virginia.
90	124		21 (11) In November 2021, the U.S. Department of Veterans
91	125		22 Affairs added the 8-milligram naloxone nasal spray to the
92	126		23 VA National Formulary.
93	127		24 (12) 70% of Americans with private health insurance
94	128		25 can access the 8-milligram naloxone nasal spray.
95	129		26 (13) 90% of Americans with Medicaid, including
96	130
97	131
98	132
99	133
100	134
101		-	SB1402 ~~Engrossed~~ - 3 - LRB103 25360 KTG 51705 b
	135	+	SB1402 - 3 - LRB103 25360 KTG 51705 b
102	136
103	137
104		-	SB1402 ~~Engrossed~~- 4 -LRB103 25360 KTG 51705 b SB1402 ~~Engrossed~~ - 4 - LRB103 25360 KTG 51705 b
105		-	SB1402 ~~Engrossed~~ - 4 - LRB103 25360 KTG 51705 b
	138	+	SB1402- 4 -LRB103 25360 KTG 51705 b SB1402 - 4 - LRB103 25360 KTG 51705 b
	139	+	SB1402 - 4 - LRB103 25360 KTG 51705 b
106	140		1 Medicaid recipients residing in Illinois, can access the
107	141		2 8-milligram naloxone nasal spray.
108	142		3 (14) The current cost of the 4-milligram naloxone
109	143		4 nasal spray is $5.93 per milligram. In contrast, the
110	144		5 8-milligram naloxone nasal spray costs 36.7% less at $3.75
111	145		6 per milligram.
112	146		7 (b) The Department of Human Services shall implement a
113	147		8 2-year pilot program to provide FDA-approved 8-milligram
114	148		9 naloxone nasal spray kits to licensed community substance use
115	149		10 providers and public health departments in Cook County, DuPage
116	150		11 County, Winnebago County, Sangamon County, and St. Clair
117	151		12 County.
118	152		13 The Department of Human Services shall implement a data
119	153		14 collection program to determine the number of 8-milligram
120	154		15 naloxone nasal spray kits administered by emergency medical
121	155		16 service providers and bystanders per overdose incident during
122	156		17 the 2-year term of the pilot program. The data collected must
123		-	18 also include the number of individuals who survived ~~as a~~
124		-	19 ~~result of~~ the 8-milligram naloxone nasal spray ~~intervention~~
125		-	20 and ~~those~~ who ~~became deceased.~~ ~~The data collected must also~~
126		-	21 ~~include~~ the ~~number of opioid overdose reversals attributed to~~
127		-	22 the ~~administration~~ of ~~the 8-milligram~~ ~~naloxone nasal spray~~
128		-	23 ~~intervention, by county.~~
129		-	24 The ~~Department of Human Services shall prepare a report on~~
130		-	25 ~~the results of the 2-year~~ ~~pilot program and submit the report~~
131		-	26 ~~to the General Assembly by July~~ 1, ~~2026~~.
	157	+	18 also include the number of individuals who survived an opioid
	158	+	19 overdose after receiving the 8-milligram naloxone nasal spray
	159	+	20 and the number of individuals who died of an opioid overdose
	160	+	21 after receiving the 8-milligram naloxone nasal spray.
	161	+	22 The Department of Human Services shall prepare a report on
	162	+	23 the results of the 2-year pilot program and submit the report
	163	+	24 to the General Assembly by July 1, 2026.
	164	+	25 Section 99. Effective date. This Act takes effect January
	165	+	26 1, 2024.
132	166
133	167
134	168
135	169
136	170
137		-	SB1402 Engrossed - 4 - LRB103 25360 KTG 51705 b
138		-
139		-
140		-	SB1402 Engrossed- 5 -LRB103 25360 KTG 51705 b SB1402 Engrossed - 5 - LRB103 25360 KTG 51705 b
141		-	SB1402 Engrossed - 5 - LRB103 25360 KTG 51705 b
142		-	1 Section 99. Effective date. This Act takes effect January
143		-	2 1, 2024.
144		-
145		-
146		-
147		-
148		-
149		-	SB1402 Engrossed - 5 - LRB103 25360 KTG 51705 b
	171	+	SB1402 - 4 - LRB103 25360 KTG 51705 b